T1	intervention 19 28	letrozole
T2	control 36 45	tamoxifen
T4	total-participants 454 457	916
T5	intervention-participants 538 541	458
T6	control-participants 567 570	458
T8	outcome 804 823	time to progression
T9	iv-cont-median 833 836	9.4
T10	cv-cont-median 839 849	6.0 months
T11	outcome 876 901	time to treatment failure
T12	iv-cont-median 911 912	9
T13	cv-cont-median 915 925	5.7 months
T14	outcome 952 983	overall objective response rate
T15	iv-bin-percent 985 988	32%
T16	cv-bin-percent 991 994	21%
T17	outcome 1025 1049	overall clinical benefit
T18	outcome 1051 1060	Median OS
T19	iv-cont-median 1118 1120	34
T20	cv-cont-median 1123 1132	30 months
T22	iv-cont-median 1497 1506	16 months
T23	cv-cont-median 1558 1566	9 months
T3	eligibility 458 515	patients with hormone receptor-positive or unknown tumors
T7	outcome 1393 1415	"time to chemotherapy"
T21	outcome 1569 1586	Time to worsening
